13-deoxydoxorubicin

13-deoxydoxorubicin is an anthracycline antitumor antibiotic and a structural analogue of doxorubicin, developed to reduce cardiotoxicity while maintaining antitumor efficacy[1][2][4][8]. It exerts its anticancer effects primarily by intercalating into DNA and inhibiting type II DNA topoisomerase (topoisomerase II), thereby preventing the religation of DNA strands during replication and transcription, which leads to cell death[1][3][4]. Unlike doxorubicin, it is not metabolized to doxorubicinol—a metabolite associated with significant cardiac toxicity—making it potentially less cardiotoxic than its parent compound[4]. The drug also stimulates reactive oxygen species production and inhibits RNA synthesis. It has been investigated in phase II clinical trials for cancer treatment but does not have established approvals for any indication[4].

Brand names

GPX-100GPX100GPX 100

Other names

13-deoxyadriamycin13-deoxydoxorubicin hydrochloride